Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Jakavi | Ruxolitinib | Myelofibrosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Kadcyla | Trastuzumab emtansine | Advanced or Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Mekinist | Trametinib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Perjeta Herceptin Combo Pack | Pertuzumab | Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Pomalyst | Pomalidomide | Multiple Myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
Revlimid | Lenalidomide | Multiple Myeloma (as maintenance therapy) | Reimburse with clinical criteria and/or conditions | Complete | ||
Stivarga (GIST) | Regorafenib | Gastrointestinal Stromal Tumour | Reimburse with clinical criteria and/or conditions | Complete | ||
Sutent | Sunitinib malate | Pancreatic Neuroendocrine Tumour | Reimburse with clinical criteria and/or conditions | Complete | ||
Sylvant | Siltuximab | Multicentric Castleman's disease (MCD) | Reimburse with clinical criteria and/or conditions | Complete | ||
Tafinlar | Dabrafenib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete |